Rapid detection of intact SARS-CoV-2 viral particles using silicon nanomembranes
Rapid detection of intact SARS-CoV-2 viral particles using silicon nanomembranes
复制标题
使用硅纳米膜快速检测完整的 SARS-CoV-2 病毒颗粒
DOI：
10.1117/12.2579733
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
McGrath, James
中科院分区：
文献类型：
--
作者：
Klaczko, Michael;Ozgurun, Baturay;Ward, Brian;Flax, Jonathan;McGrath, James
SARS-CoV-2大流行揭示了需要快速和廉价的诊断测试，以实现基于人群的活动性感染筛查。无论是标准的诊断测试，检测和测量病毒RNA（通过聚合酶链反应），或血清学检测（通过酶联免疫吸附试验）有能力明确确定活动性感染。前者是由于缺乏区分可复制和惰性病毒RNA的能力，后者是由于不同的免疫应答（从潜伏到完全缺乏免疫应答）。尽管有许多公司生产快速护理点（POC）测试，但没有一家公司能够解决全球范围内所需的测试规模，也很少有公司能够帮助解决日益严重的测试资源短缺问题。在这里，我们讨论了我们对开发高度可制造的微流体装置的努力，该装置可以从约20 μL的鼻粘液或痰中立即指示活跃的病毒感染状态，并且不需要外部电源。该装置的特点是在丙烯酸主体内的生物素功能化硅纳米膜，包含用于样品引入和分析的通道和端口。病毒捕获和目标确认分别使用基于亲和力的捕获和基于大小的遮挡来完成。该装置的模块化是通过珠粒和牛痘病毒捕获来证明的，因为我们正致力于用纯SARS-CoV-2病毒和人体样本进行测试。在所有方面取得成功后，我们可以实现一种廉价的POC诊断方法，可以确定个人的感染状况，有助于当前和未来大流行的遏制工作。除了直接病毒检测外，我们的方法还可用作快速POC样品制备工具，其限制了PCR试剂对那些已经通过我们的设备显示病毒大小和基于抗原的阳性的样品的应用。
The SARS-CoV-2 pandemic has revealed the need for rapid and inexpensive diagnostic testing to enable population-based screening for active infection. Neither standard diagnostic testing, the detection and measurement of viral RNA (via polymerase chain reaction), or serological testing (via enzyme-linked immunosorbent assay) has the capability to definitively determine active infection. The former due to a lack of ability to distinguish between replicable and inert viral RNA, and the latter due to varying immune responses (ranging from latent to a complete lack of immune response altogether). Despite many companies producing rapid point-of-care (POC) tests, none will address the global scale of testing needed and few help to combat the ever growing issue of testing resource scarcity. Here we discuss our efforts towards the development of a highly manufacturable, microfluidic device that instantly indicates active viral infection status from ~ 20 μL of nasal mucus or phlegm and requires no external power. The device features a biotin functionalized silicon nanomembrane within an acrylic body containing channels and ports for sample introduction and analysis. Virus capture and target confirmation are done using affinity-based capture and size-based occlusion respectively. Modularity of the device is proven with bead and vaccinia virus capture as we work towards testing with both pure SARS-CoV-2 virus and human samples. With success on all fronts, we could achieve an inexpensive POC diagnostic which can determine an individual’s infection status, aiding containment efforts in the current and future pandemics. In addition to direct viral detection, our method can be used as a rapid POC sample preparation tool that limits the application of PCR reagents to those samples which already display viral size and antigen-based positivity through our device.
登录
查看更多内容
影响因子：
9.5
作者：
J. Winans;Karl J. P. Smith;T. Gaborski;J. Roussie;J. McGrath
通讯作者：
J. Winans;Karl J. P. Smith;T. Gaborski;J. Roussie;J. McGrath
影响因子：
17.1
作者：
Gaborski TR;Snyder JL;Striemer CC;Fang DZ;Hoffman M;Fauchet PM;McGrath JL
通讯作者：
McGrath JL
DOI：
10.1016/j.dsx.2020.04.020
发表时间：
2020-07-01
影响因子：
10
作者：
Astuti, Indwiani;Ysrafil
通讯作者：
Ysrafil
影响因子：
13.3
作者：
Alec T. Salminen;Jingkai Zhang;G. Madejski;T. Khire;R. Waugh;J. McGrath;T. Gaborski
通讯作者：
Alec T. Salminen;Jingkai Zhang;G. Madejski;T. Khire;R. Waugh;J. McGrath;T. Gaborski
影响因子：
--
作者：
Acuti Martellucci C;Flacco ME;Cappadona R;Bravi F;Mantovani L;Manzoli L
通讯作者：
Manzoli L